SCHEMBL1680358

SCHEMBL1680358

[CH2]OC1C=Cc2ccccc21

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 2/20 0.38
HTR6 P50406 1/20 0.37
RET P07949 1/20 0.34
SIGMAR1 Q99720 2/20 0.31
CYP2D6 P10635 2/20 0.31
KDM4E B2RXH2 2/20 0.31
BRD4 O60885 1/20 0.31
CCL2 P13500 1/20 0.31
LMNA P02545 1/20 0.31
TP53 P04637 1/20 0.31
CHRM2 P08172 1/20 0.31
CYP3A4 P08684 1/20 0.31
CHRM1 P11229 1/20 0.31
DRD2 P14416 1/20 0.31
ADRA2B P18089 1/20 0.31
ADRA2C P18825 1/20 0.31
NFKB1 P19838 1/20 0.31
CHRM3 P20309 1/20 0.31
SLC6A2 P23975 1/20 0.31
HTR2C P28335 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5150447 0.78 HTR2A (0.38) HTR2AHTR6RETSIGMAR1CYP2D6
SCHEMBL1680359 0.78 RET (0.38) HTR2AHTR6RETSIGMAR1CYP2D6
SCHEMBL7197990 0.78 HTR2A (0.38) HTR2AHTR6RETSIGMAR1CYP2D6
SCHEMBL5718862 0.78 RET (0.39) HTR2AHTR6RETSIGMAR1CYP2D6
SCHEMBL29723819 0.75 SLC6A2 (0.38) HTR2AHTR6RETSIGMAR1SLC6A2
SCHEMBL5370598 0.74 HTR2A (0.34) HTR2AHTR6RETCYP2D6KDM4E
SCHEMBL6700611 0.74 POLB (0.39) HTR2AHTR6RETSIGMAR1CYP2D6
SCHEMBL5033507 0.74 RET (0.35) HTR2AHTR6RETSIGMAR1CYP2D6
SCHEMBL9495808 0.74 RET (0.35) HTR2AHTR6RETSIGMAR1CYP2D6
SCHEMBL4516491 0.74 RET (0.42) HTR2AHTR6RETSIGMAR1CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11142611-B2 Aliphatic polycarbonate resin for forming partition, partition material, substrate and production method therefor, production method for wiring substrate, and wiring forming method SUMITOMO SEIKA CHEMICALS CO., LTD. (JP) 2021-10-12 US disclosed
US-20190119440-A1 ALIPHATIC POLYCARBONATE RESIN FOR FORMING PARTITION, PARTITION MATERIAL, SUBSTRATE AND PRODUCTION METHOD THEREFOR, PRODUCTION METHOD FOR WIRING SUBSTRATE, AND WIRING FORMING METHOD SUMITOMO SEIKA CHEMICALS CO., LTD. (JP) 2019-04-25 US disclosed
EP-3441417-A1 ALIPHATIC POLYCARBONATE RESIN FOR FORMING PARTITION, PARTITION MATERIAL, SUBSTRATE AND PRODUCTION METHOD THEREFOR, PRODUCTION METHOD FOR WIRING SUBSTRATE, AND WIRING FORMING METHOD Sumitomo Seika Chemicals CO. LTD. (JP) 2019-02-13 EP disclosed
US-20110195999-A1 NOVEL ANTIFUNGAL AGENT CONTAINING HETEROCYCLIC COMPOUND NAKAMOTO KAZUTAKA 2011-08-11 US disclosed
US-7932272-B2 Antifungal agent containing heterocyclic compound EISAI R&D MANAGEMENT CO., LTD. (JP) 2011-04-26 US disclosed
US-7829585-B2 Antifungal agent containing pyridine derivative EISAI R&D MANAGEMENT CO., LTD. (JP) 2010-11-09 US disclosed
US-20090062348-A1 Antifungal Agent Containing Pyridine Derivative EISAI R&D MANAGEMENT CO., LTD. (JP) 2009-03-05 US disclosed
EP-1864980-A1 ANTIFUNGAL AGENT CONTAINING PYRIDINE DERIVATIVE Eisai R&D Management Co., Ltd. (JP) 2007-12-12 EP disclosed
US-20070105943-A1 Novel antifungal agent containing heterocyclic compound EISAI R&D MANAGEMENT CO., LTD. (JP) 2007-05-10 US disclosed
US-7074798-B2 Xanthine derivative and DPPIV inhibitor EISAI CO., LTD (JP) 2006-07-11 US disclosed
EP-1669348-A1 NOVEL ANTIFUNGAL AGENT COMPRISING HETEROCYCLIC COMPOUND Eisai Co., Ltd. (JP) 2006-06-14 EP disclosed
EP-1338595-B1 Xanthine derivatives as DPP-IV inhibitors EISAI CO LTD (JP) 2006-05-03 EP disclosed
US-20040082570-A1 Xanthine derivative and DPPIV inhibitor EISAI CO., LTD. (JP) 2004-04-29 US disclosed
EP-1338595-A2 Xanthine derivatives as DPP-IV inhibitors Eisai Co., Ltd. (JP) 2003-08-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040082570-A1 Xanthine derivative and DPPIV inhibitor DPP4, DPP9, DPP7 HTR2A 1359/4885HTR6 548/4885RET 857/4885
US-20110195999-A1 NOVEL ANTIFUNGAL AGENT CONTAINING HETEROCYCLIC COMPOUND ERG28, CYP51A1, XPO1 HTR2A 3780/4885HTR6 4269/4885RET 4438/4885
US-20070105943-A1 Novel antifungal agent containing heterocyclic compound ERG28, DPM1, CYP51A1 HTR2A 3773/4885HTR6 4266/4885RET 4478/4885
US-20090062348-A1 Antifungal Agent Containing Pyridine Derivative ERG28, SQOR, CYP51A1 HTR2A 3565/4885HTR6 3055/4885RET 4555/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.